Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Borislava G. Pavlova"'
Autor:
Friedrich Maritsch, Ingeborg Cil, Colin McKinnon, Jesse Potash, Nicole Baumgartner, Valérie Philippon, Borislava G. Pavlova
Publikováno v:
BMC Medical Ethics, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Sharing anonymized/de-identified clinical trial data and publishing research outcomes in scientific journals, or presenting them at conferences, is key to data-driven scientific exchange. However, when data from scientific publica
Externí odkaz:
https://doaj.org/article/7bf20aead1dc4484a2a5a83baf687c13
Autor:
Jerzy Windyga MD, PhD, Margarita Timofeeva MD, Oleksandra Stasyshyn MD, PhD, Vasily Mamonov MD, PhD, José Luis Lamas Castellanos MD, Toshko Lissitchkov MD, PhD, Krzysztof Chojnowski MD, PhD, Miranda Chapman BSc, Borislava G. Pavlova PhD, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonac
Externí odkaz:
https://doaj.org/article/7998488d886248d198a60d98265dfc0e
Autor:
Margarita Timofeeva, Vasily Mamonov, Krzysztof Chojnowski, Jerzy Windyga, Srilatha Tangada, Oleksandra Stasyshyn, Miranda Chapman, Borislava G. Pavlova, José Luis Lamas Castellanos, Toshko Lissitchkov
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Clinical and Applied Thrombosis/Hemostasis
Clinical and Applied Thrombosis/Hemostasis
Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonac
Autor:
Srilatha D Tangada, Eva-Maria Muchitsch, Gerald Schrenk, Borislava G. Pavlova, Werner Höllriegl, Frank M. Horling, Peter Turecek, Artur Mitterer, Hanspeter Rottensteiner, Brigitt Abbühl, Herbert Gritsch, Barbara Dietrich, Alexandra Schiviz, Birgit M. Reipert, Miranda Chapman, Friedrich Scheiflinger
Publikováno v:
Expert Review of Clinical Pharmacology. 8:163-177
Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding episodes, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and child
Autor:
Isabella Presch, Sandor Fritsch, Frank W.G. Leebeek, Peter A. Kouides, Ortrun Obermann-Slupetzky, Joan Cox Gill, Bruce M. Ewenstein, Margaret V. Ragni, Jerzy Windyga, Borislava G. Pavlova, Miranda Chapman, Giancarlo Castaman
Publikováno v:
Blood, 126(17), 2038-2046. American Society of Hematology
This phase 3 trial evaluated the safety and hemostatic efficacy of a recombinant von Willebrand factor (rVWF) for treatment of bleeds in severe von Willebrand disease (VWD). rVWF was initially administered together with recombinant factor VIII (rFVII
Autor:
B. Valenta-Singer, Miranda Chapman, T. Andreeva, Borislava G. Pavlova, Oleksandra Stasyshyn, Tomasz Urasiński, F. G. Perina, Brigitt E. Abbuehl, L. Rusen, Myungshin Oh
Publikováno v:
Haemophilia. 21:196-203
A newly developed recombinant factor IX (BAX326(1) ) was investigated for prophylactic use in paediatric patients aged12 years with severe (FIX level1%) or moderately severe (FIX level 1-2%) haemophilia B. The aim of this prospective clinical trial w
Autor:
B. Valenta-Singer, W. B. Knowlton, Brigitt E. Abbuehl, Tomasz Urasiński, J. L. Lamas, L. Rusen, Margit Serban, F. G. Perina, Borislava G. Pavlova, M. H. Solano Trujillo, Myungshin Oh, Oleksandra Stasyshyn
Publikováno v:
Haemophilia. 20:674-681
The ability to switch between coagulation factors safely is of common interest to haemophilia patients and treating physicians. This is the first formal prospective comparative evaluation of safety, efficacy and incremental recovery of a plasma-deriv
Autor:
Oleksandra Stasyshyn, Sandor Fritsch, Miranda Chapman, W.-Y. Wong, Jerzy Windyga, Vasily Mamonov, Toshko Lissitchkov, H. Ghandehari, Borislava G. Pavlova, Brigitt E. Abbuehl
Publikováno v:
Haemophilia. 20:651-658
Summary Haemostatic management of haemophilia B patients undergoing surgery is critical to patient safety. The aim of this ongoing prospective trial was to investigate the haemostatic efficacy and safety of a recombinant factor IX (rFIX) (Bax326) in
Autor:
Julia Singer, Jennifer Doralt, Eva-Maria Poellabauer, Christian Neubauer, Barbara Valenta-Singer, Sandor Fritsch, Borislava G. Pavlova, Hartmut J. Ehrlich
Publikováno v:
Vaccine. 31:3611-3616
Since the introduction of the meningococcal C conjugate (MCC) vaccine in the pediatric population in 1999, numerous clinical studies have confirmed the immunogenicity and safety of the NeisVac-C® vaccine, and several have observed a strong immune re
Autor:
B. Brand, T Dvorak, Tung Wynn, M.-F. López Fernández, Brigitt E. Abbuehl, Laimonas Griskevicius, Miranda Chapman, Borislava G. Pavlova, Ralph A. Gruppo
Publikováno v:
Haemophilia, Malden : Wiley-Blackwell Publishing, Inc, 2016, Vol. 22, p. e251-e258
Introduction BAX 855 is a pegylated full-length recombinant factor VIII (rFVIII) with an extended half-life, built on a licensed rFVIII (ADVATE®). BAX 855 demonstrated efficacy and safety in prophylaxis and the treatment of bleeding episodes in prev